MYB | V-myb avian myeloblastosis viral oncogene homolog | Cancer-related genes Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
NOXO1 | NADPH oxidase organizer 1 | FDA approved drug targets
| | | | | Tissue enhanced |
NPY4R | Neuropeptide Y receptor Y4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
NXPE2 | Neurexophilin and PC-esterase domain family, member 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
OTOP2 | Otopetrin 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
PADI2 | Peptidyl arginine deiminase, type II | Enzymes
| | | | | Tissue enhanced |
PAX4 | Paired box 4 | Disease related genes Predicted secreted proteins Transcription factors
| | | | | Tissue enhanced |
PDE6A | Phosphodiesterase 6A, cGMP-specific, rod, alpha | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
PIGZ | Phosphatidylinositol glycan anchor biosynthesis, class Z | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PIRT | Phosphoinositide-interacting regulator of transient receptor potential channels | Predicted membrane proteins
| | | | | Tissue enhanced |
PKIB | Protein kinase (cAMP-dependent, catalytic) inhibitor beta | | | | | | Tissue enhanced |
PLA2G2A | Phospholipase A2, group IIA (platelets, synovial fluid) | Enzymes FDA approved drug targets Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PPP1R1B | Protein phosphatase 1, regulatory (inhibitor) subunit 1B | | | | | | Tissue enhanced |
PTGDR | Prostaglandin D2 receptor (DP) | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
PTPRO | Protein tyrosine phosphatase, receptor type, O | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RETNLB | Resistin like beta | Predicted secreted proteins
| | | | | Tissue enhanced |
RP11-187E13.1 | Uncharacterized protein | | | | | | Tissue enhanced |
RXFP4 | Relaxin/insulin-like family peptide receptor 4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
SAMD13 | Sterile alpha motif domain containing 13 | | | | | | Tissue enhanced |
SEMA4G | Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SLC28A2 | Solute carrier family 28 (concentrative nucleoside transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC9A2 | Solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ST6GALNAC1 | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
TFF3 | Trefoil factor 3 (intestinal) | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TRABD2A | TraB domain containing 2A | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TRIM31 | Tripartite motif containing 31 | | | | | | Tissue enhanced |
TSPAN1 | Tetraspanin 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
ZG16 | Zymogen granule protein 16 | Predicted secreted proteins
| | | | | Tissue enhanced |